CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY(R) (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER
PR93814
SUZHOU, China, Dec. 21, 2021 /PRNewswire=KYODO JBN/ --
CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that
the National Medical Products Administration ("NMPA") of China has approved the
new drug application ("NDA") of anti-PD-L1 monoclonal antibody Cejemly(R)
(sugemalimab) in combination with chemotherapy for treatment-naïve metastatic
(stage IV) non-small cell lung cancer ("non-small cell lung caner" or "NSCLC")
patients.
Key Highlights
-Anti-PD-L1 monoclonal antibody Cejemly(R) approved in combination with
pemetrexed and carboplatin as first-line treatment of patients with metastatic
nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations; and in
combination with paclitaxel and carboplatin as first-line treatment of patients
with metastatic squamous NSCLC.
-It is the first anti-PD-L1 plus chemotherapy approved for the first-line
treatment of metastatic non-squamous and squamous NSCLC patients worldwide.
-The NDA of Cejemly(R) in stage III NSCLC is under regulatory review, and the
product has the potential to provide an anti-PD-L1 monoclonal antibody option
for both stage III and stage IV non-small cell lung cancer patents in the
future.
-Cejemly(R) is CStone's third new drug approval in China in 2021, following two
first-in-class precision medicines GAVRETO® and AYVAKIT®.
Globally, the incidence of lung cancer continues to rise, and it is still the
leading cause of cancer death worldwide, with huge unmet medical needs.
According to statistics, there were 2.21 million new lung cancer cases
worldwide in 2020. NSCLC accounts for about 85% of all lung cancer cases, and
about 66% of patients are diagnosed with stage III/IV NSCLC. According to
IQVIA's Global Oncology Trends, the size of global oncology drug market is
estimated to reach US$269 billion by 2025, of which immuno-oncology drugs will
contribute about 20%.
Dr. Frank Jiang, Chairman and CEO of CStone, said: "Cejemly(R) is our third
approved new drug in China this year. This further demonstrates CStone's
ability and track record in developing and commercializing high-quality new
drugs. As a drug supported by China's national science innovation program,
Cejemly(R) is a globally leading anti-PD-L1 monoclonal antibody. We will work
closely with Pfizer to leverage resources and advantages of both sides to
accelerate commercialization so that more Chinese patients can benefit from
this innovative therapy soon."
Professor Caicun Zhou, Principal Investigator of the GEMSTONE-302
registrational phase III clinical study of Cejemly(R) and Director of the
Department of Oncology, Shanghai Pulmonary Hospital, said, "The latest data
show that Cejemly(R) plus chemotherapy further prolonged progression-free
survival ("PFS") of treatment-naïve patients with stage IV NSCLC. Compared with
chemotherapy alone, Cejemly(R) plus chemotherapy demonstrated durable survival
benefits with lower toxicity and immunogenicity risks. With a unique dual
mechanism of action, Cejemly(R) mobilizes both T cells and macrophages to
destroy tumor cells. Therefore, Cejemly(R) is expected to reshape the landscape
of lung cancer treatment."
Dr. Jason Yang, Chief Medical Officer of CStone, said, "We are thrilled that
Cejemly(R) has been approved in Mainland China. It took only four years for
Cejemly(R) to obtain the first NDA approval in lung cancer from the initiation
of the phase I clinical trial in humans. It comprehensively showcased CStone's
robust clinical strategy, innovative trial design and rapid execution, while
once again demonstrating the 'CStone Speed'. We will continue to work with our
partner to pursue regulatory discussions for Cejemly(R) on the NDAs of stage
III and stage IV NSCLC with regulators in multiple countries and regions,
including the U.S. Food and Drug Administration, and bring this innovative
immunotherapy to more lung cancer patients soon. We will also continue to
advance the registrational studies of Cejemly(R) in esophageal squamous cell
carcinoma, gastric cancer, relapsed/refractory extranodal natural killer/T-cell
lymphoma, to benefit more cancer patients."
The NMPA approval is based on the positive data of GEMSTONE-302 study, a
multi-center, randomized, double-blind, phase III study that evaluated the
efficacy and safety of Cejemly(R)or placebo in combination with chemotherapy in
first-line stage IV NSCLC patients. Compared with placebo plus chemotherapy,
Cejemly(R) plus chemotherapy lowered the risk of disease progression or death
by 52%, significantly prolonged the patients' PFS and an encouraging trend in
overall survival ("OS") was observed. The clinical benefit was irrespective of
NSCLC pathologies and PD-L1 expression levels. Cejemly(R) has a well-tolerated
safety profile, and no new safety signals were found.
Apart from the approved indication, the NMPA accepted the NDA of Cejemly(R) as
consolidation therapy in patients with unresectable stage III NSCLC without
disease progression after concurrent or sequential chemoradiotherapy in
September 2021. The product has the potential to become an anti-PD-L1
monoclonal antibody approved to cover stage III and stage IV NSCLC in all-comer
settings.
About Cejemly(R) (sugemalimab)
The potential best-in-class anti-PD-L1 monoclonal antibody Cejemly(R)
(sugemalimab) is an investigational anti-PD-L1 monoclonal antibody discovered
by CStone. Authorized by the U.S.-based Ligand Corporation, Cejemly(R) is
developed by the OmniRat® transgenic animal platform, which can generate fully
human antibodies in one stop. As a fully human, full-length anti-PD-L1
monoclonal antibody, Cejemly(R) mirrors the natural G-type immunoglobulin 4
(IgG4) human antibody, which reduces the risk of immunogenicity and potential
toxicities in patients, a unique advantage over similar drugs.
Currently, the China NMPA has approved the potential best-in-class anti-PD-L1
monoclonal antibody Cejemly(R) in combination with chemotherapy for the
treatment of treatment-naïve patients with stage IV NSCLC. In addition,
Cejemly(R) is being investigated in a number of ongoing clinical trials,
including one Phase II registrational study for lymphoma and four Phase III
registrational studies in stage III NSCLC, stage IV NSCLC, gastric cancer, and
esophageal cancer, respectively.
CStone formed a strategic collaboration agreement with Pfizer that includes the
development and commercialization of Cejemly(R) in mainland China, and a
framework to bring additional oncology assets to the Greater China market.
About the GEMSTONE-302 Study
The GEMSTONE-302 study (ClinicalTrials.gov registration number: NCT03789604;
drug clinical trial registration number: CTR20181452) is a randomized,
double-blind Phase III study, designed to evaluate the efficacy and safety of
anti-PD-L1 monoclonal antibody Cejemly(R) combined with chemotherapy as the
first-line treatment in treatment-naïve patients with stage IV NSCLC vs.
placebo combined with chemotherapy. The primary endpoint of the study was
investigator-assessed PFS. Secondary endpoints included OS, BICR-assessed PFS
and safety, etc.
In August 2020, the GEMSTONE-302 study met its primary endpoint of
significantly prolonged PFS, with the risk of disease progression or death
reduced by 50% with Cejemly(R) combined with chemotherapy compared to placebo
combined with chemotherapy, as assessed by iDMC at the planned interim
analysis. Specific study data were presented in a Proffered Paper Oral
Presentation (Late-Breaking Abstract) at the ESMO Asia 2020.
In July 2021, the final analysis of PFS from the GEMSTONE-302 study showed that
Cejemly(R) in combination with chemotherapy demonstrated further improvement in
PFS and the risk of disease progression or death was reduced by 52%, together
with a trend of OS benefits. Data were presented in a Mini Oral Presentation
(Late-Breaking Abstract) at the IASLC 2021 World Conference on Lung Cancer.
About CStone
CStone is a biopharmaceutical company focused on researching, developing, and
commercializing innovative immuno-oncology and precision medicines to address
the unmet medical needs of cancer patients in China and worldwide. Established
in 2015, CStone has assembled a world-class management team with extensive
experience in innovative drug development, clinical research, and
commercialization. The Company has built an oncology-focused pipeline of 15
drug candidates with a strategic emphasis on immuno-oncology combination
therapies. Currently, CStone has received four drug approvals in Greater China,
including three in Mainland China and one in Taiwan. CStone's vision is to
become globally recognized as a world-renowned biopharmaceutical company by
bringing innovative oncology therapies to cancer patients worldwide.
For more information about CStone, please visit: www.cstonepharma.com.
About Pfizer: Breakthroughs That Change Patients' Lives
At Pfizer, Pfizer applies science and our global resources to bring therapies
to people that extend and significantly improve their lives. Pfizer strives to
set the standard for quality, safety and value in the discovery, development
and manufacture of health care products, including innovative medicines and
vaccines. Every day, Pfizer colleagues work across developed and emerging
markets to advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our responsibility as one
of the world's premier innovative biopharmaceutical companies, Pfizer
collaborates with health care providers, governments and local communities to
support and expand access to reliable, affordable health care around the world.
For more than 170 years, Pfizer has worked to make a difference for all who
rely on Pfizer.
For more information about Pifzer, please visit www.pfizer.com.cn.
Cautionary Statement required by Rule 18A.05 of the Listing Rules: THE COMPANY
CANNOT GUARANTEE THAT WE MAY BE ABLE TO ULTIMATELY DEVELOP AND MARKET
CEJEMLY(R) (SUGEMALIMAB) SUCCESSFULLY. Shareholders of the Company and
potential investors are advised to exercise due care when dealing in the shares
of the Company
Source: CStone Pharmaceuticals
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。